Cellectis ADR
Cellectis ADR (CLLS) Historical Volatility
CLLS's 30 day historical volatility is 130.33%, in the 88th percentile of readings over the past year. This is a high percentile, meaning Cellectis ADR shares have swung far more than usual. CLLS's 30 day implied volatility sits at 81.73%, with an IV Rank of 9.13%, leaving IV 48.60 points below historical volatility. This means options are pricing in less movement than the stock has actually delivered, as of Nov 16, 2026.
Read more
Tracking CLLS historical volatility helps you see how much Cellectis ADR's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, CLLS's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor CLLS 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. CLLS's 30 day historical volatility, or CLLS HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing CLLS's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 16, 2026
As of Nov 16, 2026
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →